Olivia & Michael Egge
Osteosarcoma Survivor & Father
Olivia Egge happily lived life like most teenagers, until her diagnosis with Osteosarcoma (OS) in February 2017, followed by a severe treatment protocol that has not advanced in forty years. This drove her parents led by father Michael to immerse themselves and all those friends and family around them into the world of OS. By day Michael may be a lawyer, but with every waking hour he has become an expert advocate in OS. Olivia has given us the inspiration to search for new cures for OS, while continually giving us the patient perspective.
David Duhamel, MD, FCCP
Dr. David Duhamel is globally known Interventional Pulmonologist and chef who has spent way too much time around cancer. His expertise will be critical as we move into the clinic, as recurring cancers often present in the lungs. He attended Georgetown University for college, medical school and his residency. He did his Fellowship in Pulmonary & Critical Care Medicine at UCSD. Dr. Duhamel has helped Boston Scientific, Cook, Pinnacle Biologics and other companies bring new technologies to cancer patients.
CEO - Cerecor
Mr. Peter S. Greenleaf is Chief Executive Officer of Cerecor, and was the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, and served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, where he led investment in emerging biopharmaceutical, medical device and diagnostic companies. He has over 20 years of experience in the biotechnology industry. He has held senior roles at Johnson & Johnson (Centocor) and Boehringer Mannheim. He is or has been a Director of Cerecor, Mirna Therapeutics, Mast Therapeutics, Savara, Takeda Vaccines (Montana), Histogenics, LigoCyte, Melinta (formerly Rib-X Pharmaceuticals, Inc.), Biotechnology Industry Organization and University of Maryland Baltimore Foundation, Inc. Mr. Greenleaf has a B.S. degree from Western Connecticut State University and an M.B.A. from St. Joseph's University.
Paul Romness, MHP
CEO - OS Therapies
Mr. Paul Romness leads OS Therapeutics with over 25 years of experience in the biopharmaceutical industry having served every function within major companies like Johnson & Johnson, Amgen and Boehringer Ingelheim. He has been directly involved in the launch of 9 major products in the industry covering indications for oncology, surgery, HIV, FSD, COPD, IPF, cardiovascular and diabetes. Throughout his professional career and within his community he has focused on and advocated for unmet medical need and getting treatments to patients. Mr. Romness graduated from American University with a B.S. in Finance and a Masters of Health Policy from George Washington University Medical Center.
Abbe Steel, MSc
CEO - HealthiVibe
Ms. Steel is an advisor to pharma sponsors in the design and implementation of patient-directed global programs that leverage data, insights and mobile/digital technology to satisfy patient/caregiver, provider, payer and regulator needs. She has more than 25 years experience working in the life sciences industry, leading clinical development and post-marketing patient-directed initiatives. She has extensive experience designing and managing large-scale clinical development programs as well as successful patient adherence, market access, clinical trial patient recruitment & retention and PRO initiatives. Ms. Steel graduated from George Washington University and has a Masters of Science in Health Communications from Boston University.